Literature DB >> 35583720

Homing in on cognition with cross-sectional analysis of sarcopenia-related measurements: the SARCOG study.

Özgür Kara1, Murat Kara2, Bayram Kaymak2, Tuğçe Cansu Kaya3, Beyza Nur Çıtır3, Mahmut Esad Durmuş3, Esra Durmuşoğlu3, Yahya Doğan4, Tülay Tiftik5, Gökhan Turan3, Eda Gürçay6, Pelin Analay2, Hasan Ocak2, Fatıma Edibe Şener3, Levent Özçakar2.   

Abstract

BACKGROUND: Cognitive impairment may cause significant decline in muscle function and physical performance via affecting the neuromotor control. AIM: To investigate the relationship between cognition and sarcopenia-related parameters in middle-aged and older adults.
METHODS: Demographic data and comorbidities of adults ≥ 45-year-old were noted. The Mini-Mental State Examination (MMSE) was used to evaluate global cognitive function. Sonographic anterior midthigh muscle thickness, handgrip strength, chair stand test (CST) and gait speed were measured. The diagnosis of sarcopenia was established if low muscle mass was combined with low muscle function. Dynapenia was defined as low grip strength or increased CST duration.
RESULTS: Among 1542 subjects (477 M, 1065 F), sarcopenia and dynapenia were detected in 22.6 and 17.2% of males, and 17.2 and 25.3% of females, respectively. Sarcopenic patients were older and had higher body mass index, higher frequencies of hypertension, diabetes mellitus and obesity. They had lower muscle thickness, grip strength in males only, CST performance in females only and gait speed than the other groups (all p < 0.05). Sarcopenic and dynapenic patients had similar MMSE scores which were lower than those of normal subjects (both p < 0.001). After adjusting for confounding factors, MMSE values were positively related with grip strength in females only, CST performance and gait speed (all p < 0.001); but not with muscle thickness in either gender.
CONCLUSION: Cognitive impairment may unfavorably affect muscle function and physical performance, but not muscle mass. Accordingly, its prompt management can help to decrease patient morbidity and mortality.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Chair stand test; Dynapenia; Gait speed; Grip strength; Quadriceps; Ultrasound

Mesh:

Year:  2022        PMID: 35583720     DOI: 10.1007/s40520-022-02145-5

Source DB:  PubMed          Journal:  Aging Clin Exp Res        ISSN: 1594-0667            Impact factor:   4.481


  27 in total

1.  Regional and total muscle mass, muscle strength and physical performance: The potential use of ultrasound imaging for sarcopenia.

Authors:  Ayşe Merve Ata; Murat Kara; Bayram Kaymak; Eda Gürçay; Banu Çakır; Hande Ünlü; Ayşen Akıncı; Levent Özçakar
Journal:  Arch Gerontol Geriatr       Date:  2019-03-19       Impact factor: 3.250

2.  A "Neuromuscular Look" to sarcopenia: Is it a movement disorder?

Authors:  Murat Kara; Levent Özçakar; Bayram Kaymak; Ayşe Merve Ata; Walter Frontera
Journal:  J Rehabil Med       Date:  2020-04-14       Impact factor: 2.912

3.  STAR-Sonographic Thigh Adjustment Ratio: A Golden Formula for the Diagnosis of Sarcopenia.

Authors:  Murat Kara; Bayram Kaymak; Ayşe Merve Ata; Özden Özkal; Özgür Kara; Aysun Baki; Gözde Şengül Ayçiçek; Semra Topuz; Sevilay Karahan; Abdullah Ruhi Soylu; Banu Çakır; Meltem Halil; Levent Özçakar
Journal:  Am J Phys Med Rehabil       Date:  2020-10       Impact factor: 2.159

Review 4.  Consequences of sarcopenia.

Authors:  Marjolein Visser; Laura A Schaap
Journal:  Clin Geriatr Med       Date:  2011-05-14       Impact factor: 3.076

Review 5.  Ultrasound imaging for sarcopenia, spasticity and painful muscle syndromes.

Authors:  Levent Özçakar; Ayşe Merve Ata; Bayram Kaymak; Murat Kara; Dinesh Kumbhare
Journal:  Curr Opin Support Palliat Care       Date:  2018-09       Impact factor: 2.302

6.  Cognitive function, gait speed decline, and comorbidities: the health, aging and body composition study.

Authors:  Hal H Atkinson; Caterina Rosano; Eleanor M Simonsick; Jeff D Williamson; Cralen Davis; Walter T Ambrosius; Stephen R Rapp; Matteo Cesari; Anne B Newman; Tamara B Harris; Susan M Rubin; Kristine Yaffe; Suzanne Satterfield; Stephen B Kritchevsky
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2007-08       Impact factor: 6.053

Review 7.  Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia.

Authors:  Jean-Yves Reginster; Cyrus Cooper; René Rizzoli; John A Kanis; Geoff Appelboom; Ivan Bautmans; Heike A Bischoff-Ferrari; Maarten Boers; Maria Luisa Brandi; Olivier Bruyère; Antonio Cherubini; Bruno Flamion; Roger A Fielding; Andrea Ildiko Gasparik; Luc Van Loon; Eugene McCloskey; Bruce H Mitlak; Alberto Pilotto; Suzanne Reiter-Niesert; Yves Rolland; Yannis Tsouderos; Marjolein Visser; Alfonso J Cruz-Jentoft
Journal:  Aging Clin Exp Res       Date:  2015-12-30       Impact factor: 3.636

8.  Long-term conditions, multimorbidity, lifestyle factors and change in grip strength over 9 years of follow-up: Findings from 44,315 UK biobank participants.

Authors:  Christopher Hurst; James C Murray; Antoneta Granic; Susan J Hillman; Rachel Cooper; Avan Aihie Sayer; Sian M Robinson; Richard M Dodds
Journal:  Age Ageing       Date:  2021-11-10       Impact factor: 10.668

9.  The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates.

Authors:  Stephanie A Studenski; Katherine W Peters; Dawn E Alley; Peggy M Cawthon; Robert R McLean; Tamara B Harris; Luigi Ferrucci; Jack M Guralnik; Maren S Fragala; Anne M Kenny; Douglas P Kiel; Stephen B Kritchevsky; Michelle D Shardell; Thuy-Tien L Dam; Maria T Vassileva
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-05       Impact factor: 6.053

10.  Diagnosing sarcopenia: Functional perspectives and a new algorithm from the ISarcoPRM.

Authors:  Murat Kara; Bayram Kaymak; Walter Frontera; Ayşe Merve Ata; Vincenzo Ricci; Timur Ekiz; Ke-Vin Chang; Der-Sheng Han; Xanthi Michail; Michael Quittan; Jae-Young Lim; Jonathan F Bean; Franco Franchignoni; Levent Özçakar
Journal:  J Rehabil Med       Date:  2021-06-21       Impact factor: 2.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.